Verastem, Inc. (VSTM) Stock Price

VSTMStock

$8.65−9.04%52W

Market Cap$783.37M

P/E—

PEG Ratio—

Div yield—

Beta0.58

VSTM Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)30.97%

Price vs S&P 500 (4W)9.59%

VGM Score60.66

Book Value / Share (Quarterly)$0.55

P/TBV (Annual)14.26x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)128.24%

Cash Flow / Share (Quarterly)$-1.90

Price vs S&P 500 (YTD)0.12%

Gross Margin (TTM)87.64%

Net Profit Margin (TTM)-231.59%

EPS (TTM)$-2.46

10-Day Avg Trading Volume7.85M

EPS Excl Extra (TTM)$-2.46

Revenue Growth (5Y)-18.97%

EPS (Annual)$-3.02

ROI (Annual)-145.64%

Gross Margin (Annual)82.86%

Net Profit Margin (5Y Avg)-1674.50%

Cash / Share (Quarterly)$1.51

Revenue Growth QoQ (YoY)1775.43%

ROA (Last FY)-85.00%

Revenue Growth TTM (YoY)3995.74%

EBITD / Share (TTM)$-1.79

ROE (5Y Avg)-154.64%

Operating Margin (TTM)-182.57%

Cash Flow / Share (Annual)$-1.89

P/B Ratio15.67x

P/B Ratio (Quarterly)6.72x

Net Income / Employee (Annual)$-2,053,600

EV / Revenue (TTM)8.33x

Net Interest Coverage (TTM)-314.86x

ROA (TTM)-94.54%

EPS Incl Extra (Annual)$-3.02

Current Ratio (Annual)3.09x

Quick Ratio (Quarterly)2.12x

3-Month Avg Trading Volume3.03M

52-Week Price Return-9.04%

Revenue / Employee (TTM)$858,100

Tangible BV / Share (Quarterly)$0.38

P/S Ratio (Annual)25.34x

Asset Turnover (Annual)0.13x

52-Week High$10.82

Operating Margin (5Y Avg)-1512.87%

EPS Excl Extra (Annual)$-3.02

CapEx CAGR (5Y)217.14%

Tangible BV CAGR (5Y)-3.85%

26-Week Price Return40.88%

Quick Ratio (Annual)2.96x

13-Week Price Return43.45%

Total Debt / Equity (Annual)1.51x

Current Ratio (Quarterly)2.25x

Enterprise Value$728.74M

Revenue / Share Growth (5Y)-42.22%

Asset Turnover (TTM)0.41x

Book Value / Share Growth (5Y)-7.04%

Revenue / Employee (Annual)$303,100

Pretax Margin (Annual)-677.59%

Cash / Share (Annual)$2.64

3-Month Return Std Dev73.99%

Gross Margin (5Y Avg)87.71%

Net Income / Employee (TTM)$-1,987,200

ROE (Last FY)-366.23%

Net Interest Coverage (Annual)-147.60x

EPS Basic Excl Extra (Annual)$-3.02

Receivables Turnover (TTM)5.66x

Total Debt / Equity (Quarterly)1.63x

EPS Incl Extra (TTM)$-2.46

Receivables Turnover (Annual)0.00x

ROI (TTM)-71.04%

P/S Ratio (TTM)8.95x

Pretax Margin (5Y Avg)-1674.08%

Revenue / Share (Annual)$0.45

Tangible BV / Share (Annual)$0.52

Price vs S&P 500 (52W)-24.57%

Year-to-Date Return12.05%

5-Day Price Return4.85%

EPS Normalized (Annual)$-3.02

ROA (5Y Avg)-83.02%

Net Profit Margin (Annual)-677.59%

Month-to-Date Return7.45%

Cash Flow / Share (TTM)$-3.92

EBITD / Share (Annual)$-2.48

Operating Margin (Annual)-556.24%

LT Debt / Equity (Annual)1.42x

ROI (5Y Avg)-90.60%

LT Debt / Equity (Quarterly)1.53x

EPS Basic Excl Extra (TTM)$-2.46

P/TBV (Quarterly)9.84x

P/B Ratio (Annual)10.17x

Inventory Turnover (TTM)6.07x

Pretax Margin (TTM)-230.65%

Book Value / Share (Annual)$0.74

Price vs S&P 500 (13W)40.76%

Beta0.58x

Revenue / Share (TTM)$0.87

ROE (TTM)-165.40%

52-Week Low$3.43

vGradeD

gGradeB

mGradeA

vgmGradeB

VSTM Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 6, 2026	-$0.45	-$0.31	+30.60%(+$0.14)
Q1 2026	May 7, 2026	-$0.47	-$0.43	+7.86%(+$0.04)
Q4 2025	Mar 4, 2026	-$0.50	-$0.46	+7.54%(+$0.04)
Q3 2025	Nov 4, 2025	-$0.61	-$0.54	+10.99%(+$0.07)
Q2 2025	Aug 7, 2025	-$0.74	-$0.63	+15.44%(+$0.11)

VSTM Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

4.27

Industry Peers — Pharmaceuticals(574)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
VSTMVerastem, Inc.	D	B	A	9.0x	3995.7%	87.6%	—	$8.65
LLYEli Lilly & Co.	D	B	A	14.9x	49.6%	83.4%	27.6%	$1257.03
JNJJohnson & Johnson	D	C	B	6.2x	7.8%	67.7%	14.9%	$255.56
ABBVABBVIE INC.	D	C	A	7.8x	10.4%	72.8%	-2.9%	$285.42
MRKMerck & Co., Inc.	D	C	A	5.4x	4.6%	77.3%	21.2%	$145.95
NVSNovartis AG	C	C	B	4.9x	3.3%	75.0%	15.3%	$150.62
AZNAstraZeneca PLC	C	B	B	4.3x	8.6%	81.3%	21.9%	$165.41
ABTAbbott Laboratories	C	C	B	3.9x	8.1%	56.8%	8.2%	$104.89
NVONovo-Nordisk A/S	B	C	C	3.5x	5.6%	80.7%	20.7%	$38.83
PFEPfizer Inc.	C	D	A	2.6x	-0.2%	74.7%	-3.5%	$29.58
VRTXVertex Pharmaceuticals Inc	D	C	B	10.1x	10.2%	86.0%	8.3%	$499.74
BMYBristol-Myers Squibb Co.	B	B	B	2.5x	3.1%	71.7%	—	$59.75
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	C	C	B	2.3x	5.0%	73.6%	-0.5%	$49.51
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	D	B	1.8x	13.4%	72.8%	-8.2%	$40.61
REGNRegeneron Pharmaceuticals Inc	C	C	A	5.2x	9.3%	86.0%	6.3%	$790.74
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	A	2.1x	3.1%	65.5%	-12.6%	$19.67
TEVATeva Pharmaceutical Industries Limited	D	C	A	2.8x	4.1%	52.9%	—	$41.50
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	6.3x	31.1%	88.5%	—	$369.06
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	A	13.8x	10.0%	—	-12.1%	$60.96
ZTSZOETIS INC.	C	C	B	3.5x	1.4%	71.6%	12.0%	$79.38
ALNYAlnylam Pharmaceuticals, Inc.	D	A	C	6.5x	95.1%	79.7%	—	$231.83
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	3215.5x	-67.6%	81.2%	—	$33.53
UTHRUnited Therapeutics Corp	C	C	B	7.2x	2.5%	86.1%	19.3%	$533.12
GMABGenmab A/S ADS	D	C	A	5.5x	22.3%	93.0%	6.8%	$37.00
VTRSViatris Inc. Common Stock	B	C	A	1.5x	4.4%	40.3%	—	$18.66
INSMInsmed, Inc.	F	A	C	18.5x	185.8%	83.5%	—	$96.27
ASNDAscendis Pharma A/S Ordinary Share	D	A	B	11.9x	113.3%	91.3%	—	$225.25
JAZZJazz Pharmaceuticals, Inc.	B	C	B	3.0x	12.6%	88.4%	-1.4%	$210.23
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	18.2x	202.4%	94.4%	—	$66.39
CORTCorcept Therapeutics Inc.	F	C	A	14.3x	16.0%	98.3%	-0.5%	$110.16
ELANElanco Animal Health Incorporated Common Stock	D	B	B	2.3x	11.9%	55.4%	29.9%	$23.55
SMMTSummit Therapeutics Inc. Common Stock	F	—	C	12187.5x	—	—	—	$14.63
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	C	B	3.1x	-0.9%	61.4%	16.5%	$13.07
BMRNBioMarin Pharmaceuticals Inc	C	C	B	3.1x	11.2%	79.6%	-17.0%	$54.68
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	8.1x	149.0%	91.5%	—	$449.74
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	213.8x	2928.4%	—	—	$84.95
CYTKCytokinetics Inc.	F	D	B	127.3x	-21.1%	—	—	$61.95
PTGXProtagonist Therapeutics, Inc	F	B	B	29.5x	34.8%	—	—	$128.75
TGTXTG Therapeutics, Inc.	D	B	B	10.3x	76.1%	82.4%	—	$53.97
AXSMAxsome Therapeutics, Inc	D	B	C	10.6x	56.9%	93.2%	—	$157.14
ARWRArrowhead Research Corporation	D	A	C	11.8x	16.9%	—	—	$55.90
ABVXAbivax SA American Depositary Shares	—	—	C	—	—	—	—	$88.13
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	5995.2x	—	—	—	$79.90
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	8.2x	-7.5%	98.2%	—	$42.94
ALKSAlkermes Inc. plc	D	C	B	4.1x	10.8%	84.6%	—	$41.22
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	789.2x	—	—	—	$241.76
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	D	C	A	2.0x	9.3%	39.3%	-18.4%	$19.18
KNSAKiniksa Pharmaceuticals International, plc Class A Ordinary Shares	D	B	A	7.3x	58.9%	89.8%	—	$78.59
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	24.7x	53.5%	70.9%	—	$86.17
LGNDLigand Pharmaceuticals Inc.	D	B	B	20.3x	54.9%	95.4%	—	$295.54
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	—	—	—	—	$142.78

About Verastem, Inc.

Verastem Inc is a late-stage development biopharmaceutical company developing novel anticancer agents targeting critical signaling pathways in cancer. The company's pipeline is focused on RAF/MEK and FAK inhibition to suppress cancer cell survival and tumor growth.

VSTM Next Earnings Report

Report dateNov 3, 2026

QuarterQ3 2026

Report timeAMC

EPS estimate-$0.43

Revenue estimate$26.37M

Also reporting on Nov 3, 2026

Scheduled date with consensus estimates — both can change before the company reports.

Earnings calendar for November 2026

VSTM Insider Transactions

SellSep 21, 2026
CALKINS DANIEL
Chief Financial Officer
Shares: 55Value: $424
SellAug 3, 2026
PATERSON DANIEL W
Chief Executive Officer
Shares: 1,302Value: $7,565

Open-market buys and sells filed with the SEC over the last 90 days. Grants, gifts and option exercises are excluded.

All insider transactions for September 2026

Companies in Related Industries

KROKronos Worldwide, Inc.Industrial Chemicals
CGEMCullinan Therapeutics, Inc. Common StockBiological Products
GLUEMonte Rosa Therapeutics, Inc. Common StockBiological Products
ODTXOdyssey Therapeutics, Inc. Common StockBiological Products
LXULSB INDUSTRIES INCIndustrial Chemicals
WLKPWESTLAKE CHEMICAL PARTNERS LPIndustrial Chemicals
DNAGinkgo Bioworks Holdings, Inc.Biological Products
SANASana Biotechnology, Inc. Common StockBiological Products

Same SIC sector, outside this company's own industry.

Analyst Sentiment

4.3

Strong Buy

Consensus rating

52-Week Range

Low$3.43

High$10.82